Literature DB >> 22491255

Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity.

Claire M Midgley1, Aleksandra Flanagan, Hai Bac Tran, Wanwisa Dejnirattisai, Kriangkrai Chawansuntati, Amonrat Jumnainsong, Wiyada Wongwiwat, Thaneeya Duangchinda, Juthathip Mongkolsapaya, Jonathan M Grimes, Gavin R Screaton.   

Abstract

Dengue virus infections are still increasing at an alarming rate in tropical and subtropical countries, underlying the need for a dengue vaccine. Although it is relatively easy to generate Ab responses to dengue virus, low avidity or low concentrations of Ab may enhance infection of FcR-bearing cells with clinical impact, posing a challenge to vaccine production. In this article, we report the characterization of a mAb, 2H12, which is cross-reactive to all four serotypes in the dengue virus group. Crystal structures of 2H12-Fab in complex with domain III of the envelope protein from three dengue serotypes have been determined. 2H12 binds to the highly conserved AB loop of domain III of the envelope protein that is poorly accessible in the mature virion. 2H12 neutralization varied between dengue serotypes and strains; in particular, dengue serotype 2 was not neutralized. Because the 2H12-binding epitope was conserved, this variation in neutralization highlights differences between dengue serotypes and suggests that significant conformational changes in the virus must take place for Ab binding. Surprisingly, 2H12 facilitated little or no enhancement of infection. These data provide a structural basis for understanding Ab neutralization and enhancement of infection, which is crucial for the development of future dengue vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22491255      PMCID: PMC3364712          DOI: 10.4049/jimmunol.1200227

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  73 in total

1.  Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine.

Authors:  M Simmons; G S Murphy; C G Hayes
Journal:  Am J Trop Med Hyg       Date:  2001-08       Impact factor: 2.345

2.  Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate.

Authors:  Y Chen; T Maguire; R E Hileman; J R Fromm; J D Esko; R J Linhardt; R M Marks
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

3.  Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody.

Authors:  Joseph J B Cockburn; M Erika Navarro Sanchez; Nickolas Fretes; Agathe Urvoas; Isabelle Staropoli; Carlos M Kikuti; Lark L Coffey; Fernando Arenzana Seisdedos; Hugues Bedouelle; Felix A Rey
Journal:  Structure       Date:  2012-01-26       Impact factor: 5.006

4.  Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry.

Authors:  B Bothner; X F Dong; L Bibbs; J E Johnson; G Siuzdak
Journal:  J Biol Chem       Date:  1998-01-09       Impact factor: 5.157

5.  Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape.

Authors:  Gregory D Gromowski; John T Roehrig; Michael S Diamond; J Ching Lee; Trevor J Pitcher; Alan D T Barrett
Journal:  Virology       Date:  2010-09-15       Impact factor: 3.616

6.  Genotype-specific neutralization and protection by antibodies against dengue virus type 3.

Authors:  James D Brien; S Kyle Austin; Soila Sukupolvi-Petty; Katie M O'Brien; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

7.  Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins.

Authors:  Lidice Bernardo; Lisset Hermida; Jorge Martin; Mayling Alvarez; Irina Prado; Carlos López; Rafael Martínez; Rosmari Rodríguez-Roche; Aida Zulueta; Laura Lazo; Delfina Rosario; Gerardo Guillén; María G Guzmán
Journal:  Arch Virol       Date:  2008-02-26       Impact factor: 2.574

8.  Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.

Authors:  Ana P Goncalvez; Ronald E Engle; Marisa St Claire; Robert H Purcell; Ching-Juh Lai
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

9.  A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein.

Authors:  Yong-Qiang Deng; Jian-Xin Dai; Guang-Hui Ji; Tao Jiang; Hua-Jing Wang; Hai-ou Yang; Weng-Long Tan; Ran Liu; Man Yu; Bao-Xue Ge; Qing-Yu Zhu; E-De Qin; Ya-Jun Guo; Cheng-Feng Qin
Journal:  PLoS One       Date:  2011-01-11       Impact factor: 3.240

10.  Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens.

Authors:  Wayne D Crill; Holly R Hughes; Mark J Delorey; Gwong-Jen J Chang
Journal:  PLoS One       Date:  2009-04-01       Impact factor: 3.240

View more
  46 in total

1.  Modeling the Role of Epitope Arrangement on Antibody Binding Stoichiometry in Flaviviruses.

Authors:  Daniel R Ripoll; Ilja Khavrutskii; Anders Wallqvist; Sidhartha Chaudhury
Journal:  Biophys J       Date:  2016-10-18       Impact factor: 4.033

Review 2.  Mapping the diverse structural landscape of the flavivirus antibody repertoire.

Authors:  Madhumati Sevvana; Richard J Kuhn
Journal:  Curr Opin Virol       Date:  2020-08-13       Impact factor: 7.090

3.  A synthetic peptide derived from domain III envelope glycoprotein of Dengue virus induces neutralizing antibody.

Authors:  J Asnet Mary; Akanitt Jittmittraphap; Siriporn Chattanadee; Pornsawan Leaungwutiwong; R Shenbagarathai
Journal:  Virus Genes       Date:  2017-09-25       Impact factor: 2.332

4.  Structural Basis of Zika Virus-Specific Antibody Protection.

Authors:  Haiyan Zhao; Estefania Fernandez; Kimberly A Dowd; Scott D Speer; Derek J Platt; Matthew J Gorman; Jennifer Govero; Christopher A Nelson; Theodore C Pierson; Michael S Diamond; Daved H Fremont
Journal:  Cell       Date:  2016-07-27       Impact factor: 41.582

5.  Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.

Authors:  Max Renner; Aleksandra Flanagan; Wanwisa Dejnirattisai; Chunya Puttikhunt; Watchara Kasinrerk; Piyada Supasa; Wiyada Wongwiwat; Kriangkrai Chawansuntati; Thaneeya Duangchinda; Alison Cowper; Claire M Midgley; Prida Malasit; Juha T Huiskonen; Juthathip Mongkolsapaya; Gavin R Screaton; Jonathan M Grimes
Journal:  Nat Immunol       Date:  2018-10-15       Impact factor: 25.606

6.  Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.

Authors:  Julia C Frei; Ariel S Wirchnianski; Jennifer Govero; Olivia Vergnolle; Kimberly A Dowd; Theodore C Pierson; Margaret Kielian; Mark E Girvin; Michael S Diamond; Jonathan R Lai
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

7.  [Three-dimensional morphology of C6/36 cells infected by dengue virus: a study based on digital holographic microscopy].

Authors:  Jian-Hai Yu; Xu-Ling Liu; Yu-Jing Liu; Xiao-En He; Yuan Hui; Bao Zhang; Li Zhu; Wei Zhao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

8.  A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.

Authors:  Atsushi Yamanaka; Tomohiro Kotaki; Eiji Konishi
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

9.  Reduced risk of disease during postsecondary dengue virus infections.

Authors:  Sandra Olkowski; Brett M Forshey; Amy C Morrison; Claudio Rocha; Stalin Vilcarromero; Eric S Halsey; Tadeusz J Kochel; Thomas W Scott; Steven T Stoddard
Journal:  J Infect Dis       Date:  2013-06-17       Impact factor: 5.226

10.  Comprehensive mapping of functional epitopes on dengue virus glycoprotein E DIII for binding to broadly neutralizing antibodies 4E11 and 4E5A by phage display.

Authors:  Julia C Frei; Margaret Kielian; Jonathan R Lai
Journal:  Virology       Date:  2015-09-02       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.